Crescent BiopharmaCBIO
13F holders, Q2 2026 (June 30)2holders −1
0new positions
1sold out
$18.00avg. 13F price*
At the end of Q2 2026, 2 institutions reported holding Crescent Biopharma Inc. (CBIO) in their 13F filings, down 1 from Q1 2026. 0 opened new positions and 1 sold out. The largest holders were Boxer Capital Management, LLC ($8.2M) and Quadrature Capital Ltd ($346K).
- Company
- Crescent Biopharma Inc.
- CUSIP
- 38000Q201
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $6.6M |
All 13F filers, Q1 2026 → Q2 2026: 362,940 shares sold, net −362,940 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Boxer Capital Management, LLC | 0.61% | No change | 453,686 | $8.2M |
| Quadrature Capital Ltd | 0.00% | Reduce -8.1% | 19,227 | $346K |
"% of holder's portfolio" is CBIO's weight in each manager's 13F, not the share of Crescent Biopharma Inc. the manager owns.